Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials
- DOI
- 10.1016/s0140-6736(24)00469-0
- Published
- 2024-04
- Container
- The Lancet
- Publisher
- Elsevier BV
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1016/s0140-6736-24-00469-0,
title = {Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials},
author = {Javed Butler and Sanjiv J Shah and Mark C Petrie and Barry A Borlaug and Steen Z Abildstrøm and Melanie J Davies and G Kees Hovingh and Dalane W Kitzman and Daniél Vega Møller and Subodh Verma and Mette Nygaard Einfeldt and Marie L Lindegaard and Søren Rasmussen and Walter Abhayaratna and Fozia Z Ahmed and Tuvia Ben-Gal and Vijay Chopra and Justin A Ezekowitz and Michael Fu and Hiroshi Ito and Małgorzata Lelonek and Vojtěch Melenovský and Bela Merkely and Julio Núñez and Eduardo Perna and Morten Schou and Michele Senni and Kavita Sharma and Peter van der Meer and Dirk Von Lewinski and Dennis Wolf and Mikhail N Kosiborod},
year = {2024},
journal = {The Lancet},
doi = {10.1016/s0140-6736(24)00469-0},
url = {https://doi.org/10.1016/s0140-6736(24)00469-0}
}RIS
TY - JOUR TI - Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials AU - Javed Butler AU - Sanjiv J Shah AU - Mark C Petrie AU - Barry A Borlaug AU - Steen Z Abildstrøm AU - Melanie J Davies AU - G Kees Hovingh AU - Dalane W Kitzman AU - Daniél Vega Møller AU - Subodh Verma AU - Mette Nygaard Einfeldt AU - Marie L Lindegaard AU - Søren Rasmussen AU - Walter Abhayaratna AU - Fozia Z Ahmed AU - Tuvia Ben-Gal AU - Vijay Chopra AU - Justin A Ezekowitz AU - Michael Fu AU - Hiroshi Ito AU - Małgorzata Lelonek AU - Vojtěch Melenovský AU - Bela Merkely AU - Julio Núñez AU - Eduardo Perna AU - Morten Schou AU - Michele Senni AU - Kavita Sharma AU - Peter van der Meer AU - Dirk Von Lewinski AU - Dennis Wolf AU - Mikhail N Kosiborod PY - 2024 JO - The Lancet DO - 10.1016/s0140-6736(24)00469-0 UR - https://doi.org/10.1016/s0140-6736(24)00469-0 ER -
APA
Butler, J., Shah, S. J., Petrie, M. C., Borlaug, B. A., Abildstrøm, S. Z., Davies, M. J., Hovingh, G. K., Kitzman, D. W., Møller, D. V., Verma, S., Einfeldt, M. N., Lindegaard, M. L., Rasmussen, S., Abhayaratna, W., Ahmed, F. Z., Ben-Gal, T., Chopra, V., Ezekowitz, J. A., Fu, M., Ito, H., Lelonek, M., Melenovský, V., Merkely, B., Núñez, J., Perna, E., Schou, M., Senni, M., Sharma, K., Meer, P. V. D., Lewinski, D. V., Wolf, D., & Kosiborod, M. N. (2024). Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials. The Lancet. https://doi.org/10.1016/s0140-6736(24)00469-0
Source records
- crossref · retrieved 2026-09-27T00:43:15.856Z